The recommended childhood and adolescent immunization schedules for 2018 have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC), the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. The schedules are revised annually to reflect current recommendations for the use of vaccines licensed by the US Food and Drug Administration.

The title page of the 2018 immunization schedule has been modified to include a table showing the common abbreviations and brand names for vaccines recommended for children and adolescents. Figure 1 provides vaccine recommendations in a single table for people from birth through 18 years of age. No changes have been made to the schedule shown in Figure 1. As in previous years, the yellow bars indicate the recommended age range for all children and contain a notation indicating the recommended dose number by age. The green bars indicate the recommended catch-up age. The purple bars designate the range for immunization for certain groups at high risk. The blue bars indicate the range of recommended doses for people in nonhigh-risk groups who may receive a vaccine, subject to individual decision-making. The white boxes show the ages when a vaccine is not recommended to be given routinely. The columns that begin with a gray-shaded box indicate vaccine recommendations for school entry and at adolescent visits.

Figure 2 is the catch-up immunization schedule offering recommendations for children and adolescents who start late or are >1 month behind. As in previous years, the catch-up schedule is divided into sections for children 4 months through 6 years of age and children and adolescents 7 years through 18 years of age. Two changes have been made to Figure 2. First, the rotavirus vaccine row has been modified to include the maximum ages for the first and last doses of the series. Second, the polio vaccine rows clarify the catch-up schedule for people 4 years of age or older.

Tables (job aids) clarify the recommended use of Haemophilus influenzae type b, pneumococcal, and pertussis-containing vaccines as a function of age, the number of doses previously administered, and the time interval since the last dose. Minor wording changes have been made for clarity, but there are no new recommendations.

Figure 3 addresses vaccines that may be indicated for people 0 through 18 years of age who have a specific medical indication. This figure now includes a reference for use of live vaccines in people with HIV.

Footnotes contain recommendations for routine vaccination, for catch-up vaccination, and for the vaccination of children and adolescents with high-risk conditions or in special circumstances. For 2018, the footnotes are presented in a new, simplified format to increase ease of use and clarity but still provide all pertinent information. Complete sentences have been replaced by bullets and redundant or unnecessary language has been removed.

Recommendations in the figures should be read with the corresponding footnotes.

Changes have been made to the following footnotes:

  • Hepatitis B: Additional information regarding the timing of the birth dose for infants with a birth weight of <2000 g who are born to mothers who are negative for hepatitis B surface antigen has been added;

  • H influenzae type b: MenHibrix (bivalent meningococcal conjugate vaccine and H influenzae type b conjugate vaccine) has been removed because the vaccine is no longer commercially available, and all remaining doses have expired;

  • Influenza: Wording has been changed to indicate that live attenuated influenza vaccine is not recommended for the 2017–2018 influenza season;

  • Meningococcal vaccines: Only quadrivalent meningococcal conjugate vaccines are discussed in footnote 11. Serogroup B meningococcal vaccines are discussed in a separate footnote (12);

  • Polio vaccines: Updated wording provides guidance for children who have received oral polio vaccine as part of their series; and

  • Measles-mumps-rubella vaccines: Guidance is provided in regard to use of a third dose of a mumps-containing vaccine during a mumps outbreak.

The 2018 version of Figures 1–3, the catch-up schedule, the footnotes, and job aids are available on the American Academy of Pediatrics Web site ( and the CDC Web site ( A parent-friendly vaccine schedule for children and adolescents is available at An adult immunization schedule is published in February of each year and is available at

Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System. Guidance about how to obtain and complete a Vaccine Adverse Event Reporting System form can be obtained at or by calling 800-822-7967. Additional information can be found in the Red Book and at Red Book Online ( Statements from the Advisory Committee on Immunization Practices and the CDC that contain detailed recommendations for individual vaccines, including recommendations for children with high-risk conditions, are available at Information on new vaccine releases, vaccine supplies, and interim recommendations resulting from vaccine shortages and statements on specific vaccines can be found at


Centers for Disease Control and Prevention

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

Carrie L. Byington, MD, FAAP, Chairperson

Yvonne A. Maldonado, MD, FAAP, Vice Chairperson

Ritu Banerjee, MD, PhD, FAAP

Elizabeth D. Barnett, MD, FAAP

James D. Campbell, MD, MS, FAAP

Jeffrey S. Gerber, MD, PhD, FAAP

Ruth Lynfield, MD, FAAP

Flor M. Munoz, MD, FAAP

Dawn Nolt, MD, MPH, FAAP

Ann-Christine Nyquist, MD, MSPH, FAAP

Sean T. O'Leary, MD, MPH, FAAP

Mobeen H. Rathore, MD, FAAP

Mark H. Sawyer, MD, FAAP

William J. Steinbach, MD, FAAP

Tina Q. Tan, MD, FAAP

Theoklis E. Zaoutis, MD, MSCE, FAAP

David W. Kimberlin, MD, FAAP – Red Book Editor

Michael T. Brady, MD, FAAP – Red Book Associate Editor

Mary Anne Jackson, MD, FAAP – Red Book Associate Editor

Sarah S. Long, MD, FAAP – Red Book Associate Editor

Henry H. Bernstein, DO, MHCM, FAAP – Red Book Online Associate Editor

H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

Amanda C. Cohn, MD, FAAP - Centers for Disease Control and Prevention

Jamie Deseda-Tous, MD - Sociedad Latinoamericana de Infectologia Pediatrica

Karen M. Farizo, MD - US Food and Drug Administration

Marc Fischer, MD, FAAP - Centers for Disease Control and Prevention

Natasha Halasa, MD, MPH, FAAP - Pediatric Infectious Diseases Society

Nicole Le Saux, MD - Canadian Paediatric Society

Scot Moore, MD, FAAP - Committee on Practice and Ambulatory Medicine

Angela K. Shen, ScD, MPH - National Vaccine Program Office

James J. Stevermer, MD, MSPH, FAAFP - American Academy of Family Physicians

Jeffrey R. Starke, MD, FAAP - American Thoracic Society

Kay M. Tomashek, MD, MPH, DTM - National Institutes of Health

Jennifer M. Frantz, MPH